Business context and reporting period
Larimar Therapeutics, Inc. (Nasdaq: LRMR) filed this Form 8-K on September 29, 2026, reporting the appointment of John B. Harlow, Jr. as President and Chief Operating Officer, effective that date. The filing concerns an executive appointment and compensation; it does not report quarterly or annual operating results.
Financial and compensation details
- Initial annual base salary: $560,000, subject to annual review.
- Cash signing bonus: $35,000.
- Annual bonus target: 40% of base salary; the 2026 target is prorated. Actual payment depends on performance objectives and generally requires continued employment through the payment date.
- Inducement equity award: options to purchase 800,000 shares, exercisable at the common stock closing price on September 29, 2026, and 50,000 restricted stock units. Vesting is subject to continued service.
- No revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics are provided in this filing.
Material changes and terms
The appointment adds a President and COO with prior commercial leadership experience at biopharmaceutical companies. The filing does not provide a prior-period financial comparison.
If the company terminates Mr. Harlow without Cause or he resigns for Good Reason, severance outside the one-year period following a Change in Control includes nine months of base-salary payments and subsidized COBRA coverage. In the one-year period following a Change in Control, the stated benefits include 12 months of payments based on base salary plus target bonus and 12 months of COBRA coverage. Benefits are subject to a release of claims. The agreement also addresses payment of an applicable prior-year earned bonus upon certain terminations, including death or disability.
Outlook, risks, and unusual items
The filing provides no company guidance or management outlook. Mr. Harlow is an at-will employee. The option and RSU awards are inducement grants under Nasdaq Listing Rule 5635(c)(4); their vesting depends on continued service. The filing does not state the option grant’s dollar value or the resulting potential compensation expense or dilution.
Key facts to verify
- Review the full employment agreement, which the company said it would file as an exhibit to its Form 10-Q for the quarter ended September 30, 2026.
- Confirm the option exercise price, grant-date valuation, vesting and any subsequent changes in the company’s filings.
- Assess the ultimate bonus earned and the compensation expense and share dilution associated with the equity awards.